As of the latest Form 4 filed Jul 7, 2026.
What Cytokinetics Inc insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 98 most recent filings for CYTK.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-07-07 | 2026-07-07 | Malik Fady Ibraham EVP Research & Development | SSale | −3.50K | $86.62 | $303K | Yes (planned) | Form 4 ↗ |
| 2026-07-07 | 2026-07-07 | Malik Fady Ibraham, EVP Research & Development | MExercise | +3.50K | $7.80 | $27.3K | Yes (planned) | Form 4 ↗ |
| 2026-07-02 | 2026-07-01 | Blum Robert I President & CEO | SSale | −7.50K | $84.92 | $637K | Yes (planned) | Form 4 ↗ |
| 2026-07-02 | 2026-07-01 | Callos Andrew EVP, Chief Commercial Officer | SSale | −15.0K | $85.80 | $1.29M | Yes (planned) | Form 4 ↗ |
| 2026-07-02 | 2026-07-01 | Callos Andrew, EVP, Chief Commercial Officer | MExercise | +15.0K | $23.26 | $349K | Yes (planned) | Form 4 ↗ |
| 2026-07-02 | 2026-07-01 | Lee Sung EVP, Chief Financial Officer | SSale | −1.11K | $87.79 | $97.6K | Yes (planned) | Form 4 ↗ |
| 2026-07-02 | 2026-07-01 | Lee Sung, EVP, Chief Financial Officer | MExercise | +1.11K | $48.51 | $53.9K | Yes (planned) | Form 4 ↗ |
| 2026-06-29 | 2026-06-29 | Lee Sung EVP, Chief Financial Officer | SSale | −3.13K | $85.00 | $266K | Yes (planned) | Form 4 ↗ |
| 2026-06-29 | 2026-06-29 | Lee Sung, EVP, Chief Financial Officer | MExercise | +823.00 | $44.36 | $36.5K | Yes (planned) | Form 4 ↗ |
| 2026-06-29 | 2026-06-29 | Lee Sung, EVP, Chief Financial Officer | MExercise | +188.00 | $44.36 | $8.34K | Yes (planned) | Form 4 ↗ |
| 2026-06-29 | 2026-06-29 | Lee Sung, EVP, Chief Financial Officer | MExercise | +1.11K | $48.51 | $54.0K | Yes (planned) | Form 4 ↗ |
| 2026-06-29 | 2026-06-29 | Lee Sung, EVP, Chief Financial Officer | MExercise | +822.00 | $44.36 | $36.5K | Yes (planned) | Form 4 ↗ |
| 2026-06-29 | 2026-06-29 | Lee Sung, EVP, Chief Financial Officer | MExercise | +188.00 | $44.36 | $8.34K | Yes (planned) | Form 4 ↗ |
| 2026-06-29 | 2026-06-24 | Lee Sung EVP, Chief Financial Officer | SSale | −38.7K | $82.30 | $3.19M | Yes (planned) | Form 4 ↗ |
| 2026-06-29 | 2026-06-24 | Lee Sung, EVP, Chief Financial Officer | MExercise | +1.11K | $48.51 | $54.0K | Yes (planned) | Form 4 ↗ |
| 2026-06-29 | 2026-06-24 | Lee Sung, EVP, Chief Financial Officer | MExercise | +822.00 | $44.36 | $36.5K | Yes (planned) | Form 4 ↗ |
| 2026-06-29 | 2026-06-24 | Lee Sung, EVP, Chief Financial Officer | MExercise | +188.00 | $44.36 | $8.34K | Yes (planned) | Form 4 ↗ |
| 2026-06-29 | 2026-06-24 | Lee Sung, EVP, Chief Financial Officer | MExercise | +1.11K | $48.51 | $54.0K | Yes (planned) | Form 4 ↗ |
| 2026-06-29 | 2026-06-24 | Lee Sung, EVP, Chief Financial Officer | MExercise | +2.82K | $44.36 | $125K | Yes (planned) | Form 4 ↗ |
| 2026-06-29 | 2026-06-24 | Lee Sung, EVP, Chief Financial Officer | MExercise | +9.31K | $44.36 | $413K | Yes (planned) | Form 4 ↗ |
| 2026-06-29 | 2026-06-24 | Lee Sung, EVP, Chief Financial Officer | MExercise | +23.4K | $48.51 | $1.13M | Yes (planned) | Form 4 ↗ |
| 2026-06-23 | 2026-06-23 | Malik Fady Ibraham EVP Research & Development | SSale | −3.50K | $79.51 | $278K | Yes (planned) | Form 4 ↗ |
| 2026-06-23 | 2026-06-23 | Malik Fady Ibraham, EVP Research & Development | MExercise | +3.50K | $7.80 | $27.3K | Yes (planned) | Form 4 ↗ |
| 2026-06-15 | 2026-06-15 | Blum Robert I President & CEO | SSale | −7.50K | $70.46 | $528K | Yes (planned) | Form 4 ↗ |
| 2026-06-09 | 2026-06-09 | Malik Fady Ibraham EVP Research & Development | SSale | −3.50K | $67.98 | $238K | Yes (planned) | Form 4 ↗ |
| 2026-06-09 | 2026-06-09 | Malik Fady Ibraham, EVP Research & Development | MExercise | +3.50K | $7.80 | $27.3K | Yes (planned) | Form 4 ↗ |
| 2026-06-01 | 2026-06-01 | Kaye Edward M. MD Director | SSale | −2.93K | $76.09 | $223K | Yes (planned) | Form 4 ↗ |
| 2026-06-01 | 2026-06-01 | Callos Andrew EVP, Chief Commercial Officer | SSale | −15.0K | $74.08 | $1.11M | Yes (planned) | Form 4 ↗ |
| 2026-06-01 | 2026-06-01 | Callos Andrew, EVP, Chief Commercial Officer | MExercise | +15.0K | $23.26 | $349K | Yes (planned) | Form 4 ↗ |
| 2026-06-01 | 2026-06-01 | PARSHALL B LYNNE Director | SSale | −5.00K | $74.08 | $370K | Yes (planned) | Form 4 ↗ |
| 2026-05-28 | 2026-05-27 | Blum Robert I President & CEO | SSale | −7.50K | $77.21 | $579K | Yes (planned) | Form 4 ↗ |
| 2026-05-27 | 2026-05-27 | Bhanji Muna Director | AAward | +2.85K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-27 | 2026-05-27 | Daly James M Director | AAward | +2.85K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-27 | 2026-05-27 | Harrington Robert Arthur Director | AAward | +2.85K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-27 | 2026-05-27 | HENDERSON JOHN T Director | AAward | +2.85K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-27 | 2026-05-27 | Kaye Edward M. MD Director | AAward | +2.85K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-27 | 2026-05-27 | PARSHALL B LYNNE Director | AAward | +2.85K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-27 | 2026-05-27 | Landry Robert E Director | AAward | +2.85K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-27 | 2026-05-27 | WIERENGA WENDELL Director | AAward | +2.85K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-27 | 2026-05-27 | Wysenski Nancy Director | AAward | +2.85K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-20 | 2026-05-19 | Malik Fady Ibraham EVP Research & Development | SSale | −3.50K | $75.69 | $265K | Yes (planned) | Form 4 ↗ |
| 2026-05-20 | 2026-05-19 | Malik Fady Ibraham, EVP Research & Development | MExercise | +3.50K | $7.80 | $27.3K | Yes (planned) | Form 4 ↗ |
| 2026-05-14 | 2026-05-14 | Blum Robert I President & CEO | SSale | −7.50K | $77.92 | $584K | Yes (planned) | Form 4 ↗ |
| 2026-05-05 | 2026-05-05 | Malik Fady Ibraham EVP Research & Development | SSale | −3.50K | $77.37 | $271K | Yes (planned) | Form 4 ↗ |
| 2026-05-05 | 2026-05-05 | Malik Fady Ibraham, EVP Research & Development | MExercise | +3.50K | $7.80 | $27.3K | Yes (planned) | Form 4 ↗ |
| 2026-05-05 | 2026-05-05 | WIERENGA WENDELL Director | SSale | −4.03K | $75.00 | $302K | Yes (planned) | Form 4 ↗ |
| 2026-05-05 | 2026-05-05 | WIERENGA WENDELL, Director | MExercise | +4.03K | $12.40 | $50.0K | Yes (planned) | Form 4 ↗ |
| 2026-05-05 | 2026-05-05 | Lee Sung EVP, Chief Financial Officer | SSale | −23.9K | $76.87 | $1.84M | Yes (planned) | Form 4 ↗ |
| 2026-05-05 | 2026-05-05 | HENDERSON JOHN T Director | SSale | −20.0K | $75.97 | $1.52M | Yes (planned) | Form 4 ↗ |
| 2026-05-05 | 2026-05-05 | HENDERSON JOHN T, Director | MExercise | +20.0K | $7.61 | $152K | Yes (planned) | Form 4 ↗ |
| 2026-05-05 | 2026-05-05 | Callos Andrew EVP, Chief Commercial Officer | SSale | −11.3K | $77.25 | $875K | Yes (planned) | Form 4 ↗ |
| 2026-05-05 | 2026-05-05 | Callos Andrew, EVP, Chief Commercial Officer | MExercise | +11.3K | $39.13 | $443K | Yes (planned) | Form 4 ↗ |
| 2026-05-04 | 2026-05-01 | Callos Andrew EVP, Chief Commercial Officer | SSale | −15.9K | $65.00 | $1.03M | Yes (planned) | Form 4 ↗ |
| 2026-05-04 | 2026-05-01 | Callos Andrew, EVP, Chief Commercial Officer | MExercise | +15.9K | $37.63 | $597K | Yes (planned) | Form 4 ↗ |
| 2026-04-30 | 2026-04-30 | Callos Andrew EVP, Chief Commercial Officer | SSale | −15.0K | $63.26 | $949K | Yes (planned) | Form 4 ↗ |
| 2026-04-30 | 2026-04-30 | Callos Andrew, EVP, Chief Commercial Officer | MExercise | +15.0K | $23.26 | $349K | Yes (planned) | Form 4 ↗ |
| 2026-04-29 | 2026-04-29 | Blum Robert I President & CEO | SSale | −7.50K | $59.62 | $447K | Yes (planned) | Form 4 ↗ |
| 2026-04-21 | 2026-04-21 | Malik Fady Ibraham EVP Research & Development | SSale | −3.50K | $65.69 | $230K | Yes (planned) | Form 4 ↗ |
| 2026-04-21 | 2026-04-21 | Malik Fady Ibraham, EVP Research & Development | MExercise | +3.50K | $7.80 | $27.3K | Yes (planned) | Form 4 ↗ |
| 2026-04-15 | 2026-04-15 | Wysenski Nancy Director | AAward | +95.00 | $65.37 | $6.21K | No | Form 4 ↗ |
| 2026-04-15 | 2026-04-15 | WIERENGA WENDELL Director | AAward | +95.00 | $65.37 | $6.21K | No | Form 4 ↗ |
| 2026-04-15 | 2026-04-15 | Kaye Edward M. MD Director | AAward | +191.00 | $65.37 | $12.5K | No | Form 4 ↗ |
| 2026-04-15 | 2026-04-15 | HENDERSON JOHN T Director | AAward | +325.00 | $65.37 | $21.2K | No | Form 4 ↗ |
| 2026-04-15 | 2026-04-15 | Harrington Robert Arthur Director | AAward | +191.00 | $65.37 | $12.5K | No | Form 4 ↗ |
| 2026-04-15 | 2026-04-15 | Daly James M Director | AAward | +191.00 | $65.37 | $12.5K | No | Form 4 ↗ |
| 2026-04-15 | 2026-04-15 | Callos Andrew EVP, Chief Commercial Officer | SSale | −7.45K | $66.02 | $492K | Yes (planned) | Form 4 ↗ |
| 2026-04-15 | 2026-04-15 | Blum Robert I President & CEO | SSale | −7.50K | $65.38 | $490K | Yes (planned) | Form 4 ↗ |
| 2026-04-08 | 2026-04-07 | Malik Fady Ibraham EVP Research & Development | SSale | −1.00K | $64.75 | $64.8K | Yes (planned) | Form 4 ↗ |
| 2026-04-08 | 2026-04-07 | Malik Fady Ibraham, EVP Research & Development | MExercise | +1.00K | $10.60 | $10.6K | Yes (planned) | Form 4 ↗ |
| 2026-04-08 | 2026-04-07 | Malik Fady Ibraham, EVP Research & Development | SSale | −3.50K | $65.21 | $228K | Yes (planned) | Form 4 ↗ |
| 2026-04-08 | 2026-04-07 | Malik Fady Ibraham, EVP Research & Development | MExercise | +3.50K | $7.80 | $27.3K | Yes (planned) | Form 4 ↗ |
| 2026-04-01 | 2026-04-01 | Blum Robert I President & CEO | SSale | −7.50K | $66.63 | $500K | Yes (planned) | Form 4 ↗ |
| 2026-03-31 | 2026-03-31 | Callos Andrew EVP, Chief Commercial Officer | SSale | −3.64K | $65.00 | $237K | Yes (planned) | Form 4 ↗ |
| 2026-03-18 | 2026-03-18 | Callos Andrew EVP, Chief Commercial Officer | SSale | −1.93K | $62.07 | $120K | Yes (planned) | Form 4 ↗ |
| 2026-03-18 | 2026-03-17 | Lee Sung EVP, Chief Financial Officer | SSale | −4.93K | $62.15 | $307K | No | Form 4 ↗ |
| 2026-03-18 | 2026-03-17 | Callos Andrew EVP, Chief Commercial Officer | SSale | −2.92K | $62.15 | $181K | No | Form 4 ↗ |
| 2026-03-18 | 2026-03-17 | Callos Andrew, EVP, Chief Commercial Officer | SSale | −5.63K | $62.15 | $350K | No | Form 4 ↗ |
| 2026-03-18 | 2026-03-17 | Malik Fady Ibraham EVP Research & Development | SSale | −4.40K | $62.15 | $273K | No | Form 4 ↗ |
| 2026-03-18 | 2026-03-17 | Malik Fady Ibraham, EVP Research & Development | SSale | −7.64K | $62.15 | $475K | No | Form 4 ↗ |
| 2026-03-18 | 2026-03-17 | Blum Robert I President & CEO | SSale | −23.9K | $62.15 | $1.49M | No | Form 4 ↗ |
| 2026-03-18 | 2026-03-17 | Blum Robert I, President & CEO | SSale | −12.7K | $62.15 | $788K | No | Form 4 ↗ |
| 2026-03-17 | 2026-03-15 | Blum Robert I President & CEO | AAward | +75.3K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-17 | 2026-03-15 | Callos Andrew EVP, Chief Commercial Officer | AAward | +13.3K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-17 | 2026-03-15 | Callos Andrew, EVP, Chief Commercial Officer | AAward | +20.6K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-17 | 2026-03-15 | Hessekiel Jeffrey Chief Legal & Admin Officer | AAward | +20.6K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-17 | 2026-03-15 | Lee Sung EVP, Chief Financial Officer | AAward | +20.6K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-17 | 2026-03-15 | Malik Fady Ibraham EVP Research & Development | AAward | +27.3K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-16 | 2026-03-16 | Callos Andrew EVP, Chief Commercial Officer | SSale | −1.71K | $61.03 | $104K | Yes (planned) | Form 4 ↗ |
| 2026-03-10 | 2026-03-09 | Callos Andrew EVP, Chief Commercial Officer | SSale | −2.58K | $60.72 | $157K | No | Form 4 ↗ |
| 2026-03-10 | 2026-03-09 | Malik Fady Ibraham EVP Research & Development | SSale | −2.91K | $60.72 | $177K | No | Form 4 ↗ |
| 2026-03-10 | 2026-03-09 | Blum Robert I President & CEO | SSale | −7.93K | $60.72 | $482K | No | Form 4 ↗ |
| 2026-03-05 | 2026-03-05 | Callos Andrew EVP, Chief Commercial Officer | MExercise | +15.0K | $23.26 | $349K | Yes (planned) | Form 4 ↗ |
| 2026-03-05 | 2026-03-05 | Callos Andrew, EVP, Chief Commercial Officer | SSale | −11.0K | $61.88 | $681K | Yes (planned) | Form 4 ↗ |
| 2026-03-05 | 2026-03-05 | Callos Andrew, EVP, Chief Commercial Officer | SSale | −15.0K | $61.87 | $928K | Yes (planned) | Form 4 ↗ |
| 2026-03-05 | 2026-03-05 | Callos Andrew, EVP, Chief Commercial Officer | MExercise | +11.0K | $39.13 | $430K | Yes (planned) | Form 4 ↗ |
| 2026-03-02 | 2026-03-02 | PARSHALL B LYNNE Director | SSale | −5.00K | $61.21 | $306K | Yes (planned) | Form 4 ↗ |
| 2026-03-02 | 2026-03-02 | Callos Andrew EVP, Chief Commercial Officer | SSale | −886.00 | $61.62 | $54.6K | Yes (planned) | Form 4 ↗ |
| 2026-03-02 | 2026-03-02 | Callos Andrew, EVP, Chief Commercial Officer | MExercise | +886.00 | $37.63 | $33.3K | Yes (planned) | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also CYTK’s full analysis or the market-wide insider trading feed. The tabs above jump to CYTK’s other SEC data.
Source: SEC Form 4 filings for CYTK, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.